1. Home
  2. CKPT vs OPP Comparison

CKPT vs OPP Comparison

Compare CKPT & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • OPP
  • Stock Information
  • Founded
  • CKPT 2014
  • OPP 2010
  • Country
  • CKPT United States
  • OPP United States
  • Employees
  • CKPT N/A
  • OPP N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • OPP Finance/Investors Services
  • Sector
  • CKPT Health Care
  • OPP Finance
  • Exchange
  • CKPT Nasdaq
  • OPP Nasdaq
  • Market Cap
  • CKPT 172.4M
  • OPP 204.1M
  • IPO Year
  • CKPT 2017
  • OPP N/A
  • Fundamental
  • Price
  • CKPT $4.04
  • OPP $8.57
  • Analyst Decision
  • CKPT Buy
  • OPP
  • Analyst Count
  • CKPT 3
  • OPP 0
  • Target Price
  • CKPT $4.33
  • OPP N/A
  • AVG Volume (30 Days)
  • CKPT 5.6M
  • OPP 108.0K
  • Earning Date
  • CKPT 03-28-2025
  • OPP 01-01-0001
  • Dividend Yield
  • CKPT N/A
  • OPP 14.41%
  • EPS Growth
  • CKPT N/A
  • OPP N/A
  • EPS
  • CKPT N/A
  • OPP N/A
  • Revenue
  • CKPT $41,000.00
  • OPP N/A
  • Revenue This Year
  • CKPT $102,182.93
  • OPP N/A
  • Revenue Next Year
  • CKPT $351.71
  • OPP N/A
  • P/E Ratio
  • CKPT N/A
  • OPP N/A
  • Revenue Growth
  • CKPT N/A
  • OPP N/A
  • 52 Week Low
  • CKPT $1.38
  • OPP $7.26
  • 52 Week High
  • CKPT $4.50
  • OPP $8.83
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 65.90
  • OPP 47.10
  • Support Level
  • CKPT $2.37
  • OPP $8.55
  • Resistance Level
  • CKPT $4.07
  • OPP $8.74
  • Average True Range (ATR)
  • CKPT 0.03
  • OPP 0.09
  • MACD
  • CKPT 0.01
  • OPP -0.01
  • Stochastic Oscillator
  • CKPT 70.00
  • OPP 29.09

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

Share on Social Networks: